INT49130

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.63
First Reported 1995
Last Reported 2010
Negated 2
Speculated 5
Reported most in Body
Documents 49
Total Number 54
Disease Relevance 27.55
Pain Relevance 4.78

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IGFBP3) extracellular region (IGFBP3) nucleus (IGFBP3)
Anatomy Link Frequency
plasma 2
colon 2
molar 2
stroma 1
epithelium 1
IGFBP3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Clonidine 31 99.84 Very High Very High Very High
dexamethasone 20 99.80 Very High Very High Very High
cINOD 14 99.74 Very High Very High Very High
aspirin 2 99.60 Very High Very High Very High
Fibrositis 30 99.00 Very High Very High Very High
rheumatoid arthritis 233 97.56 Very High Very High Very High
Bioavailability 43 95.84 Very High Very High Very High
agonist 19 95.52 Very High Very High Very High
Arthritis 14 83.04 Quite High
antagonist 20 81.20 Quite High
Disease Link Frequency Relevance Heat
Thyroid Disease 89 100.00 Very High Very High Very High
Diabetes Mellitus 23 99.98 Very High Very High Very High
Cancer 149 99.64 Very High Very High Very High
Precocious Puberty 9 99.52 Very High Very High Very High
Apoptosis 512 99.48 Very High Very High Very High
Chronic Renal Failure 168 99.28 Very High Very High Very High
Targeted Disruption 275 99.16 Very High Very High Very High
Laron Syndrome 30 99.16 Very High Very High Very High
Hypothyroidism 6 99.12 Very High Very High Very High
Sleep Disorders 416 99.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Dexamethasone does not increase IGF-I and IGFBP-3 levels in man in the absence of endogenous GH.
Neg (not) Positive_regulation (increase) of IGFBP-3 associated with dexamethasone
1) Confidence 0.63 Published 2001 Journal J. Endocrinol. Invest. Section Title Doc Link 11817711 Disease Relevance 0.08 Pain Relevance 0.27
It has been previously shown that short-term glucocorticoid administration increases circulating IGF-I and IGFBP-3 levels both in men and rats.
Positive_regulation (increases) of IGFBP-3
2) Confidence 0.63 Published 2001 Journal J. Endocrinol. Invest. Section Abstract Doc Link 11817711 Disease Relevance 0.08 Pain Relevance 0.18
They found that IGFBP-3 mRNA and protein were equivalent in normal epithelium and underlying stroma.
Positive_regulation (equivalent) of IGFBP-3 in stroma
3) Confidence 0.50 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2409350 Disease Relevance 1.10 Pain Relevance 0
There was a significantly greater increase in IGF-I and IGFBP-3 in the first month in patients who experienced hGH-related adverse events compared with those who did not.
Positive_regulation (increase) of IGFBP-3
4) Confidence 0.49 Published 1997 Journal Clin. Endocrinol. (Oxf) Section Body Doc Link 9196611 Disease Relevance 0 Pain Relevance 0
In the adult-onset patients there was an increased risk of adverse events in heavier patients and those who had the greatest increases in IGF-I and IGFBP-3 at 1 month of therapy.


Positive_regulation (increases) of IGFBP-3
5) Confidence 0.49 Published 1997 Journal Clin. Endocrinol. (Oxf) Section Body Doc Link 9196611 Disease Relevance 0 Pain Relevance 0
On the other hand, using aspirin/NSAIDs appeared to increase IGFBP-3 levels significantly among pre-menopausal Hispanic women.
Spec (appeared) Positive_regulation (increase) of IGFBP-3 associated with aspirin, endometriosis (extended) and cinod
6) Confidence 0.47 Published 2005 Journal Cancer Causes Control Section Abstract Doc Link 16215864 Disease Relevance 0.43 Pain Relevance 0.15
The frequency of the IGFBP3 C allele differed between Hispanic (0.65) and non-Hispanic white women (0.53), but serum levels of IGFBP-3 were lower for Hispanic women than non-Hispanic after accounting for IGFBP3 genotype.
Positive_regulation (accounting) of IGFBP3
7) Confidence 0.47 Published 2005 Journal Cancer Causes Control Section Abstract Doc Link 16215864 Disease Relevance 0.51 Pain Relevance 0.12
Dietary factors including sodium butyrate [38] and retinoic acid [39] induced IGFBP-3 in gut epithelial cells as well as protect against neoplasia.
Positive_regulation (induced) of IGFBP-3 in gut associated with cancer
8) Confidence 0.47 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2409350 Disease Relevance 0.91 Pain Relevance 0
In cancer tissue, however, IGFBP-3 mRNA was elevated and this reflected increased expression in the stroma but diminished or absent expression in malignant epithelium [15,38].
Positive_regulation (elevated) of IGFBP-3 in epithelium associated with malignant neoplastic disease and cancer
9) Confidence 0.47 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2409350 Disease Relevance 1.04 Pain Relevance 0
Serum ferritin concentration correlated significantly with GH peak response to provocation (r = -0.36, P < 0.05) and circulating IGF-I (r = -0.47, P < 0.01) and IGFBP-3 (r = -0.42, P < 0.01) concentrations.
Positive_regulation (response) of IGFBP-3
10) Confidence 0.46 Published 1998 Journal Eur. J. Endocrinol. Section Abstract Doc Link 9578506 Disease Relevance 0.63 Pain Relevance 0.13
In the IGF-I generation test, after GH injection, the thalassaemic children had significantly lower IGF-I and IGFBP-3 levels 86.7 +/- 11.2 ng/ml and 2.05 +/- 0.51 mg/l respectively) than those in the CSS group (226 +/- 45.4 ng/ml and 2.8 +/- 0.43 mg/l respectively).
Positive_regulation (levels) of IGFBP-3 associated with growth problems
11) Confidence 0.46 Published 1998 Journal Eur. J. Endocrinol. Section Abstract Doc Link 9578506 Disease Relevance 0.60 Pain Relevance 0.06
GH response to provocation and circulating IGF-I and IGF-binding protein-3 concentrations, the IGF-I generation test and clinical response to GH therapy in children with beta-thalassaemia.
Positive_regulation (response) of IGF-binding protein-3 associated with thalassemia
12) Confidence 0.46 Published 1998 Journal Eur. J. Endocrinol. Section Title Doc Link 9578506 Disease Relevance 0.62 Pain Relevance 0.16
Measurement of IGFBP-3
Positive_regulation (Measurement) of IGFBP-3
13) Confidence 0.46 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2671651 Disease Relevance 0.31 Pain Relevance 0
Measurement of IGFBP-3
Positive_regulation (Measurement) of IGFBP-3
14) Confidence 0.46 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2669552 Disease Relevance 0.31 Pain Relevance 0
Furthermore, our finding of increased IGF-1 and IGFBP-3 levels after GH treatment, over 4 days, opens up the possibility of testing the therapeutic potential of hGH in patients with FM.
Positive_regulation (increased) of IGFBP-3 associated with fibrositis
15) Confidence 0.46 Published 1999 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 10487713 Disease Relevance 0.70 Pain Relevance 0.35
After dexamethasone administration there were no significant changes either in IGF-I or IGFBP-3 values (10.7 +/- 4.1 and 1,110 +/- 214 microg/l, respectively).
Positive_regulation (values) of IGFBP-3 associated with dexamethasone
16) Confidence 0.45 Published 2001 Journal J. Endocrinol. Invest. Section Abstract Doc Link 11817711 Disease Relevance 0.09 Pain Relevance 0.30
However, to our knowledge, no studies have previously evaluated tissue IGFBP-3 mRNA in normal colonic mucosa in relation to adenoma risk.
Positive_regulation (evaluated) of tissue IGFBP-3 associated with adenoma
17) Confidence 0.44 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2409350 Disease Relevance 0.95 Pain Relevance 0
Our findings that reduced expression of tissue IGFBP-3 mRNA in the normal colon is associated with increased risk of colorectal adenomas are compatible with evidence in experimental animal models indicating that elevated tissue IGFBP-3 protects against colon carcinogenesis [11].
Positive_regulation (elevated) of tissue IGFBP-3 in colon associated with adenoma
18) Confidence 0.44 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2409350 Disease Relevance 1.06 Pain Relevance 0.03
We found that increased IGFBP3 decreases both hypocretin mRNA, and hypocretin peptide content in hypothalamus and target areas (Fig. 3A–C).
Positive_regulation (increased) of IGFBP3 in hypothalamus
19) Confidence 0.44 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2617764 Disease Relevance 0.93 Pain Relevance 0.03
Although we found no IGFBP3 autoantibodies nor a genetic association with IGFBP3 polymorphisms in human narcolepsy, we found that an IGFBP3 polymorphism known to increase serum IGFBP3 levels was associated with lower CSF hypocretin-1 in normal individuals.


Positive_regulation (increase) of IGFBP3 associated with sleep disorders
20) Confidence 0.44 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2617764 Disease Relevance 0.69 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox